A phase I/II study of the safety and efficacy of [ < sup > 177 < /sup > Lu]Lu-satoreotide tetraxetan in advanced somatostatin receptor-positive neuroendocrine tumours

CONCLUSION: [177Lu]Lu-satoreotide tetraxetan, administered at a median cumulative activity of 13.0 GBq over three cycles, has an acceptable safety profile with a promising clinical response in patients with progressive, SSTR-positive NETs. A 5-year long-term follow-up study is ongoing.TRIAL REGISTRATION: ClinicalTrials.gov, NCT02592707. Registered October 30, 2015.PMID:37721581 | DOI:10.1007/s00259-023-06383-1

Source: Molecular Medicine - September 18, 2023 Category: Molecular Biology Authors: Damian Wild Henning Gr ønbæk Shaunak Navalkissoor Alexander Haug Guillaume P Nicolas Ben Pais Catherine Ansquer Jean-Mathieu Beauregard Alexander McEwan Michael Lassmann Daniele Pennestri Magali Volteau Nat P Lenzo Rodney J Hicks Source Type: research